Effect of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion on Parkinson's Disease–Related Pain: A 6‐Month Real‐World Longitudinal Study

BACKGROUND: Foslevodopa/foscarbidopa (LDp/CDp) infusion may reduce PD-related pain; however, its effects on different pain manifestations remain unclear. OBJECTIVE: The aim was to evaluate longitudinal changes in overall and domain-specific PD-related pain after LDp/CDp infusion. METHODS: Twenty-six patients with advanced PD initiating LDp/CDp infusion underwent evaluation at baseline (T0) and 6 months (T1). Pain was assessed using the King's Parkinson's Disease Pain Scale (KPPS). Secondary outcomes included motor complications, quality of life (QoL), dopaminergic treatment burden, and pain-motor correlations. RESULTS: At T1, KPPS total score decreased (9.6 ± 6.5 vs. 2.7 ± 4.7, P < 0.001), with improvements in chronic (P = 0.01), fluctuation-related (P < 0.001), and nocturnal (P < 0.001) pain. Motor complications reduced (P < 0.001), and fluctuation-related pain reduction correlated with motor complication changes (ρ = 0.46, P = 0.04). QoL improved (P = 0.006), whereas dopaminergic treatment burden was unchanged. CONCLUSIONS: LDp/CDp infusion improved PD-related pain, particularly chronic, fluctuation-related, and nocturnal pain, with a parallel improvement in QoL, suggesting benefits beyond motor complication management.